| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Neuromyelitis Optica | 6 | 2020 | 397 | 1.96 | Why? |
| Multiple Sclerosis | 19 | 2021 | 2600 | 1.92 | Why? |
| Myelin-Oligodendrocyte Glycoprotein | 6 | 2019 | 80 | 1.48 | Why? |
| Aquaporin 4 | 7 | 2020 | 69 | 0.85 | Why? |
| Optic Neuritis | 4 | 2018 | 132 | 0.80 | Why? |
| Central Nervous System Diseases | 3 | 2020 | 410 | 0.71 | Why? |
| Autoantibodies | 6 | 2019 | 2094 | 0.65 | Why? |
| Demyelinating Diseases | 2 | 2018 | 224 | 0.64 | Why? |
| Estrogens | 1 | 2018 | 252 | 0.57 | Why? |
| Multiple Sclerosis, Relapsing-Remitting | 5 | 2019 | 529 | 0.57 | Why? |
| Cyclophosphamide | 4 | 2017 | 387 | 0.52 | Why? |
| Multiple Sclerosis, Chronic Progressive | 4 | 2018 | 136 | 0.51 | Why? |
| Testosterone | 1 | 2018 | 596 | 0.48 | Why? |
| Immunosuppressive Agents | 7 | 2021 | 6331 | 0.47 | Why? |
| Spinal Cord Diseases | 2 | 2018 | 141 | 0.45 | Why? |
| Neuritis, Autoimmune, Experimental | 2 | 2019 | 2 | 0.39 | Why? |
| Sciatic Nerve | 2 | 2019 | 26 | 0.38 | Why? |
| Spinal Cord | 3 | 2018 | 281 | 0.37 | Why? |
| Encephalomyelitis | 2 | 2018 | 75 | 0.36 | Why? |
| Oligodendroglia | 2 | 2018 | 57 | 0.35 | Why? |
| Rituximab | 3 | 2021 | 1096 | 0.35 | Why? |
| Ketocholesterols | 2 | 2018 | 48 | 0.35 | Why? |
| Hydroxycholesterols | 2 | 2018 | 85 | 0.33 | Why? |
| Guillain-Barre Syndrome | 1 | 2020 | 1495 | 0.33 | Why? |
| Disability Evaluation | 4 | 2018 | 671 | 0.31 | Why? |
| Fatty Acids | 2 | 2018 | 238 | 0.31 | Why? |
| Methylprednisolone | 3 | 2019 | 2107 | 0.31 | Why? |
| Magnetic Resonance Imaging | 7 | 2020 | 6551 | 0.30 | Why? |
| Potassium | 2 | 2018 | 325 | 0.28 | Why? |
| France | 11 | 2021 | 12074 | 0.28 | Why? |
| Immunologic Factors | 5 | 2021 | 4206 | 0.27 | Why? |
| Sjogren's Syndrome | 1 | 2006 | 284 | 0.24 | Why? |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 2 | 2019 | 40 | 0.23 | Why? |
| Paraparesis | 1 | 2020 | 17 | 0.22 | Why? |
| Nerve Fibers | 2 | 2018 | 73 | 0.22 | Why? |
| Vitamin B 12 Deficiency | 1 | 2021 | 57 | 0.22 | Why? |
| Reflex, Abnormal | 1 | 2020 | 27 | 0.22 | Why? |
| Asthenia | 1 | 2020 | 107 | 0.21 | Why? |
| Antibodies, Monoclonal, Humanized | 5 | 2021 | 9335 | 0.21 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.20 | Why? |
| Paresthesia | 1 | 2020 | 134 | 0.20 | Why? |
| Quadriplegia | 1 | 2020 | 109 | 0.20 | Why? |
| Natalizumab | 2 | 2018 | 144 | 0.20 | Why? |
| Ataxia | 1 | 2020 | 133 | 0.19 | Why? |
| Antibodies, Viral | 7 | 2021 | 51949 | 0.19 | Why? |
| Shaw Potassium Channels | 1 | 2018 | 2 | 0.19 | Why? |
| Biotin | 1 | 2018 | 52 | 0.19 | Why? |
| Paraneoplastic Syndromes, Nervous System | 1 | 2017 | 4 | 0.18 | Why? |
| Oxysterols | 1 | 2018 | 28 | 0.18 | Why? |
| Demyelinating Autoimmune Diseases, CNS | 1 | 2018 | 27 | 0.18 | Why? |
| Small Fiber Neuropathy | 1 | 2018 | 14 | 0.18 | Why? |
| Neural Conduction | 1 | 2020 | 261 | 0.18 | Why? |
| Vision Disorders | 2 | 2018 | 260 | 0.18 | Why? |
| Vitamin B Complex | 1 | 2018 | 49 | 0.18 | Why? |
| Alemtuzumab | 1 | 2019 | 121 | 0.18 | Why? |
| Peripheral Nervous System Diseases | 2 | 2018 | 193 | 0.18 | Why? |
| Permeability | 1 | 2019 | 238 | 0.18 | Why? |
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2017 | 39 | 0.18 | Why? |
| Bacteriuria | 1 | 2017 | 31 | 0.18 | Why? |
| Tears | 1 | 2001 | 400 | 0.17 | Why? |
| Fingolimod Hydrochloride | 1 | 2019 | 217 | 0.17 | Why? |
| Brain | 6 | 2020 | 5133 | 0.17 | Why? |
| Cervical Vertebrae | 1 | 2018 | 151 | 0.17 | Why? |
| Infusions, Intravenous | 2 | 2019 | 1224 | 0.17 | Why? |
| Leukoencephalopathy, Progressive Multifocal | 1 | 2017 | 55 | 0.16 | Why? |
| Neurologists | 1 | 2020 | 283 | 0.16 | Why? |
| High-Intensity Interval Training | 1 | 2017 | 83 | 0.16 | Why? |
| Mycophenolic Acid | 1 | 2019 | 383 | 0.16 | Why? |
| Immunoglobulins, Intravenous | 2 | 2020 | 2705 | 0.16 | Why? |
| Kaplan-Meier Estimate | 2 | 2018 | 4260 | 0.16 | Why? |
| Action Potentials | 1 | 2018 | 368 | 0.16 | Why? |
| Facial Paralysis | 1 | 2020 | 231 | 0.16 | Why? |
| Matrix Metalloproteinase 9 | 1 | 2017 | 211 | 0.16 | Why? |
| Treatment Outcome | 6 | 2020 | 51732 | 0.15 | Why? |
| Adult | 31 | 2021 | 244371 | 0.15 | Why? |
| Immunoglobulin G | 8 | 2021 | 21571 | 0.14 | Why? |
| Particulate Matter | 2 | 2018 | 3249 | 0.14 | Why? |
| Nitrogen Dioxide | 1 | 2018 | 488 | 0.14 | Why? |
| Blood-Brain Barrier | 1 | 2019 | 531 | 0.14 | Why? |
| Microglia | 1 | 2018 | 357 | 0.14 | Why? |
| Humans | 52 | 2021 | 930598 | 0.14 | Why? |
| Myalgia | 1 | 2020 | 1015 | 0.14 | Why? |
| Resistance Training | 1 | 2017 | 273 | 0.14 | Why? |
| Disease Progression | 7 | 2018 | 13580 | 0.13 | Why? |
| Sex Characteristics | 1 | 2021 | 1120 | 0.13 | Why? |
| Imaging, Three-Dimensional | 1 | 2018 | 680 | 0.13 | Why? |
| Female | 34 | 2021 | 380317 | 0.13 | Why? |
| Male | 36 | 2021 | 367725 | 0.13 | Why? |
| Autophagy | 2 | 2018 | 960 | 0.13 | Why? |
| Homeostasis | 1 | 2017 | 582 | 0.12 | Why? |
| Middle Aged | 27 | 2021 | 270681 | 0.12 | Why? |
| Ageusia | 1 | 2020 | 918 | 0.12 | Why? |
| Purines | 1 | 2017 | 816 | 0.11 | Why? |
| Visual Acuity | 2 | 2018 | 790 | 0.11 | Why? |
| Neurodegenerative Diseases | 1 | 2017 | 469 | 0.11 | Why? |
| Recurrence | 3 | 2018 | 3675 | 0.11 | Why? |
| Peptide Fragments | 2 | 2018 | 2075 | 0.10 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2018 | 1153 | 0.10 | Why? |
| Young Adult | 11 | 2021 | 93724 | 0.10 | Why? |
| Serologic Tests | 2 | 2021 | 4359 | 0.10 | Why? |
| Glucocorticoids | 1 | 2006 | 4431 | 0.10 | Why? |
| Air Pollutants | 2 | 2018 | 3110 | 0.10 | Why? |
| Ozone | 1 | 2018 | 757 | 0.10 | Why? |
| Rats, Inbred Lew | 2 | 2019 | 45 | 0.10 | Why? |
| Exanthema | 1 | 2019 | 1097 | 0.09 | Why? |
| Connective Tissue Diseases | 1 | 2011 | 187 | 0.09 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 1261 | 0.09 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.09 | Why? |
| Interferons | 1 | 2021 | 2885 | 0.09 | Why? |
| Age Distribution | 1 | 2018 | 3567 | 0.09 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.09 | Why? |
| Patient Compliance | 1 | 2018 | 1468 | 0.09 | Why? |
| Terminology as Topic | 1 | 2013 | 546 | 0.09 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 1458 | 0.09 | Why? |
| Diarrhea | 1 | 2020 | 2743 | 0.09 | Why? |
| Antibodies, Neutralizing | 4 | 2021 | 25288 | 0.08 | Why? |
| Retrospective Studies | 11 | 2021 | 105322 | 0.08 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.08 | Why? |
| Environmental Exposure | 1 | 2017 | 1558 | 0.08 | Why? |
| Neurology | 1 | 2018 | 1613 | 0.08 | Why? |
| Databases, Factual | 2 | 2018 | 6248 | 0.08 | Why? |
| Brain Diseases | 1 | 2018 | 1463 | 0.08 | Why? |
| Adolescent | 10 | 2021 | 86841 | 0.08 | Why? |
| Chronic Disease | 2 | 2013 | 5139 | 0.07 | Why? |
| Drug Administration Schedule | 2 | 2017 | 2324 | 0.07 | Why? |
| Immunotherapy | 1 | 2019 | 2421 | 0.07 | Why? |
| Injections, Intravenous | 1 | 2006 | 381 | 0.07 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.07 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 7868 | 0.07 | Why? |
| Immunoassay | 1 | 2020 | 4485 | 0.07 | Why? |
| Animals | 9 | 2019 | 78931 | 0.07 | Why? |
| Registries | 2 | 2020 | 12327 | 0.06 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.06 | Why? |
| Biological Products | 1 | 2018 | 2331 | 0.06 | Why? |
| Kinetics | 2 | 2021 | 3238 | 0.06 | Why? |
| Anti-Inflammatory Agents | 2 | 2019 | 6153 | 0.06 | Why? |
| Isoelectric Focusing | 1 | 2001 | 10 | 0.06 | Why? |
| Healthy Volunteers | 2 | 2018 | 1444 | 0.06 | Why? |
| Silver Staining | 1 | 2001 | 12 | 0.06 | Why? |
| Air Pollution | 2 | 2018 | 3504 | 0.06 | Why? |
| Paraparesis, Spastic | 1 | 2001 | 3 | 0.06 | Why? |
| Cohort Studies | 4 | 2020 | 36005 | 0.06 | Why? |
| Olfaction Disorders | 1 | 2020 | 3704 | 0.06 | Why? |
| Double-Blind Method | 3 | 2018 | 5988 | 0.06 | Why? |
| Societies, Medical | 1 | 2018 | 6907 | 0.06 | Why? |
| Walking | 1 | 2006 | 442 | 0.06 | Why? |
| Nitrous Oxide | 1 | 2021 | 58 | 0.06 | Why? |
| Time Factors | 4 | 2021 | 31397 | 0.05 | Why? |
| Rats | 2 | 2019 | 2764 | 0.05 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.05 | Why? |
| Vitamin B 12 | 1 | 2021 | 132 | 0.05 | Why? |
| Biomarkers | 4 | 2018 | 23361 | 0.05 | Why? |
| Neurites | 1 | 2019 | 26 | 0.05 | Why? |
| Receptors, Lysosphingolipid | 1 | 2019 | 25 | 0.05 | Why? |
| Diffuse Cerebral Sclerosis of Schilder | 1 | 2018 | 2 | 0.05 | Why? |
| Exercise Test | 1 | 2006 | 911 | 0.05 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.05 | Why? |
| Nervous System Diseases | 1 | 2018 | 4092 | 0.05 | Why? |
| Sodium Channels | 1 | 2018 | 7 | 0.05 | Why? |
| Proteostasis Deficiencies | 1 | 2018 | 9 | 0.05 | Why? |
| Merkel Cells | 1 | 2018 | 1 | 0.05 | Why? |
| Drug Therapy, Combination | 2 | 2019 | 7268 | 0.05 | Why? |
| Myelin Sheath | 1 | 2018 | 41 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.05 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.05 | Why? |
| Potassium Channels | 1 | 2018 | 33 | 0.05 | Why? |
| Receptors, GABA | 1 | 2017 | 2 | 0.05 | Why? |
| Cell Line, Transformed | 1 | 2018 | 87 | 0.05 | Why? |
| Pregnanolone | 1 | 2017 | 5 | 0.05 | Why? |
| Vidarabine | 1 | 2018 | 59 | 0.05 | Why? |
| Myelin Basic Protein | 1 | 2017 | 24 | 0.05 | Why? |
| Antipyretics | 1 | 2019 | 107 | 0.05 | Why? |
| Predictive Value of Tests | 1 | 2013 | 9537 | 0.04 | Why? |
| Dose-Response Relationship, Drug | 2 | 2018 | 3776 | 0.04 | Why? |
| Epidermis | 1 | 2018 | 47 | 0.04 | Why? |
| Aged | 9 | 2021 | 215776 | 0.04 | Why? |
| Mice, Mutant Strains | 1 | 2017 | 42 | 0.04 | Why? |
| Macular Degeneration | 1 | 2001 | 194 | 0.04 | Why? |
| Mice, Inbred Strains | 1 | 2017 | 136 | 0.04 | Why? |
| Sarcoidosis | 1 | 2001 | 271 | 0.04 | Why? |
| Histamine Antagonists | 1 | 2019 | 203 | 0.04 | Why? |
| Gray Matter | 1 | 2018 | 150 | 0.04 | Why? |
| Neurotransmitter Agents | 1 | 2017 | 57 | 0.04 | Why? |
| Databases, Chemical | 1 | 2018 | 196 | 0.04 | Why? |
| Preliminary Data | 1 | 2018 | 457 | 0.04 | Why? |
| Leg | 1 | 2018 | 142 | 0.04 | Why? |
| Antibody Specificity | 1 | 2021 | 1328 | 0.04 | Why? |
| Antigens, CD20 | 1 | 2016 | 105 | 0.04 | Why? |
| Motor Activity | 1 | 2018 | 217 | 0.04 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.04 | Why? |
| Immunoenzyme Techniques | 1 | 2018 | 448 | 0.04 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.04 | Why? |
| Reference Values | 1 | 2018 | 795 | 0.04 | Why? |
| Rheumatic Diseases | 1 | 2011 | 2675 | 0.04 | Why? |
| Protective Factors | 1 | 2021 | 1720 | 0.04 | Why? |
| Intention to Treat Analysis | 1 | 2016 | 673 | 0.04 | Why? |
| White Matter | 1 | 2018 | 369 | 0.04 | Why? |
| Muscle Strength | 1 | 2017 | 317 | 0.04 | Why? |
| Expert Testimony | 1 | 2018 | 658 | 0.03 | Why? |
| Intellectual Disability | 1 | 2001 | 391 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2021 | 9893 | 0.03 | Why? |
| Meta-Analysis as Topic | 1 | 2021 | 1289 | 0.03 | Why? |
| Proton Pump Inhibitors | 1 | 2019 | 377 | 0.03 | Why? |
| Cross-Over Studies | 1 | 2017 | 867 | 0.03 | Why? |
| Blood Proteins | 1 | 2017 | 551 | 0.03 | Why? |
| Mice | 3 | 2018 | 21357 | 0.03 | Why? |
| Immunoglobulin M | 2 | 2021 | 9091 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Vascular Endothelial Growth Factor A | 1 | 2017 | 604 | 0.03 | Why? |
| Acute Disease | 1 | 2006 | 6029 | 0.03 | Why? |
| Ligands | 1 | 2017 | 1300 | 0.03 | Why? |
| Exercise Tolerance | 1 | 2017 | 634 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2018 | 1136 | 0.03 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.03 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.03 | Why? |
| Phosphoproteins | 1 | 2021 | 4346 | 0.03 | Why? |
| Mitochondria | 1 | 2018 | 857 | 0.03 | Why? |
| Data Collection | 1 | 2020 | 1769 | 0.03 | Why? |
| Structure-Activity Relationship | 1 | 2017 | 2219 | 0.03 | Why? |
| Immunohistochemistry | 1 | 2018 | 2275 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2017 | 2437 | 0.03 | Why? |
| Multivariate Analysis | 1 | 2021 | 5440 | 0.03 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.03 | Why? |
| Convalescence | 1 | 2021 | 2829 | 0.02 | Why? |
| Image Processing, Computer-Assisted | 1 | 2018 | 1383 | 0.02 | Why? |
| Cross Reactions | 1 | 2021 | 4374 | 0.02 | Why? |
| Cell Proliferation | 1 | 2017 | 1973 | 0.02 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.02 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.02 | Why? |
| HEK293 Cells | 1 | 2021 | 8394 | 0.02 | Why? |
| Myelitis, Transverse | 1 | 2011 | 218 | 0.02 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.02 | Why? |
| Gene Expression | 1 | 2017 | 3332 | 0.02 | Why? |
| International Cooperation | 1 | 2020 | 3436 | 0.02 | Why? |
| Disabled Persons | 1 | 2017 | 1152 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.02 | Why? |
| Cells, Cultured | 1 | 2017 | 5835 | 0.02 | Why? |
| Skin | 1 | 2018 | 2096 | 0.02 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2020 | 6740 | 0.02 | Why? |
| Seasons | 1 | 2018 | 4071 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2016 | 4758 | 0.02 | Why? |
| Environmental Monitoring | 1 | 2017 | 3143 | 0.02 | Why? |
| Information Dissemination | 1 | 2020 | 2986 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2018 | 17020 | 0.02 | Why? |
| RNA, Messenger | 1 | 2017 | 5131 | 0.02 | Why? |
| RNA, Viral | 2 | 2020 | 32276 | 0.02 | Why? |
| B-Lymphocytes | 1 | 2016 | 4418 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.01 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.01 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.01 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.01 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2018 | 10998 | 0.01 | Why? |
| T-Lymphocytes | 1 | 2016 | 6670 | 0.01 | Why? |
| Chi-Square Distribution | 1 | 2001 | 961 | 0.01 | Why? |
| Statistics, Nonparametric | 1 | 2001 | 1008 | 0.01 | Why? |
| Incidence | 1 | 2019 | 25622 | 0.01 | Why? |
| Italy | 1 | 2021 | 38444 | 0.01 | Why? |
| Syndrome | 1 | 2001 | 1310 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.01 | Why? |
| Cytokines | 1 | 2017 | 15010 | 0.01 | Why? |
| Inflammation | 1 | 2017 | 13255 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.01 | Why? |
| Child | 1 | 2020 | 70012 | 0.01 | Why? |